{"id":"NCT01119937","sponsor":"Novartis Pharmaceuticals","briefTitle":"Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients","officialTitle":"A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of NVA237 (50µg o.d.) Using Tiotropium (18µg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2011-11","completion":null,"firstPosted":"2010-05-10","resultsPosted":"2013-01-18","lastUpdate":"2013-01-18"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"NVA237","otherNames":[]},{"type":"DRUG","name":"Tiotropium","otherNames":[]}],"arms":[{"label":"NVA237","type":"EXPERIMENTAL"},{"label":"Tiotropium","type":"EXPERIMENTAL"}],"summary":"This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .","primaryOutcome":{"measure":"Number of Participants With Adverse Events, Serious Adverse Events or Death","timeFrame":"52 weeks","effectByArm":[{"arm":"NVA237","deltaMin":102,"sd":null},{"arm":"Tiotropium","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":40,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":123},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease","Hypertension","Bronchitis","Constipation"]}}